We believe that clinical adoption of psychedelic therapies represents an opportunity to reduce human suffering on an unprecedented scale.
The Psychedelic Action Task Force is a first-of-its-kind coalition of leading scientists and clinicians working to redress the UK mental health crisis.
Founded by world-renowned scientist Prof David Nutt and award-winning human rights campaigner Alex Adams, and co-steered by esteemed psychotherapist Dr Leyla Hussein OBE, Psychedelic Action will be advocating for evidence-based drug policy reform, conducting a revaluation of current clinical paradigms, and developing a roadmap to facilitate the integration of psychedelic therapy into the UK healthcare system.
If you would like to be part of the largest scientist- and clinician-led movement of its kind, join us by clicking the link below and completing the short form.
Our Clinical Working Group comprises ~150 world-leading experts in the fields of neuroscience, psychiatry, pharmacology, and psychology, including:
Prof David Baldwin MA DM FRCPsych FHEA FRSA
University of Southampton
Prof Stephen Bazire FRPharmS FCMHP MBE
University of East Anglia
Prof Anthony Cleare BSc MBBS PhD FRCPsych
King’s College London
Prof Philip Cowen MA PhD FRCPsych
University of Oxford
Prof Val Curran BSc MSc PhD
University College London
Prof Bill Deakin PhD FRCPsych FMedSci
University of Manchester
Prof Barry Everitt ScD FRS FMedSci
University of Cambridge
Prof Jeremy Hall MB BS PhD MRCPsych
Cardiff University
Prof Catherine Harmer DPhil MA DipLATHE
University of Oxford
Prof Paul Harrison DM FRCPsych FMedSci
University of Oxford
Prof Joseph Hayes MBChB MRCPsych PhD
University College London
Prof Sunjeev Kamboj PhD
University College London
Prof George Kirov MD PhD
Cardiff University
Prof Celia Morgan PhD
University of Exeter
Prof Jo Neill PhD
University of Manchester
Prof David Nutt DM FRCP FRCPsych FMedSci DLaws
Imperial College London
Prof Emma Robinson BSc PhD
University of Bristol
Prof Trevor Robbins CBE FRS FMedSci
University of Cambridge
Prof Deepak Srivastava PhD ScD FRSB
King’s College London
Prof Clare Stanford PhD
University College London
Prof James Stone MBBS PhD FRCPsych
University of Sussex
Prof Allan Young MB ChB MPhil MD FRCPsych FRCPC
Imperial College London
Prof Adam R. Winstock MBBS BSc MSc MD MRCP MRCPsych FAChAM
University College London
Our StoryPsychedelic Action has been formed in the belief that current legislation, which prohibits the clinical use of psychedelic compounds (including MDMA, LSD, psilocybin and DMT) outside the context of research trials specifically licensed by the Home Office, is unjustifiable.
After more than 50 years of prohibition, criminalisation and stigmatisation, science is finally showing that certain psychedelics when used according to established protocols in clinical settings are not usually dangerous or harmful.
Instead, when used according to tested, safe and ethical guidelines, they are the next revolution in mental health treatment.
In the context of a growing mental health crisis and lack of adequate tools to treat a plethora of psychiatric conditions, including PTSD, depression, anxiety, and addiction, the potential of psychedelic therapies to treat such conditions - for which there is strong data in support - can no longer be ignored.
The UK is failing patients most at need, enduring the severe economic consequences of the mental health crisis, and missing an opportunity to be a pioneering hub for mental health treatment.
We believe the need for systemic change is now a moral imperative and that this should be led by clinicians and scientists, free from commercial and political influence.